Selective N-Type Calcium Channel Blockers for Pain Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current calcium channel blockers lack selectivity for N-type channels over L-type channels, leading to potential hypotensive effects, and there is a need for novel compounds that can effectively block N-type calcium channels to treat various disorders without these side effects.
Innovation Solution
Development of azetidinyl, pyrrolidinyl, and hexahydroazepinyl compounds represented by Formula I, which act as selective N-type calcium channel blockers, along with their pharmaceutically acceptable salts, prodrugs, and solvates, for use in treating disorders such as pain, stroke, and neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective calcium channel blockers are used to block calcium channels, then calcium influx is inhibited and neurological disorders are treated, but hypotensive effects occur due to L-type channel inhibition
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (azetidinyl, pyrrolidinyl, piperidinyl, or hexahydroazepinyl groups combined with benzenesulfonamide) that confer selective affinity for N-type calcium channels. This structural specificity enables the drug to act locally on target channels in the nervous system while sparing L-type channels in the cardiovascular system, thus treating neurological disorders without causing hypotension.
Solution Approach 2:
The patent employs parameter changes by optimizing specific molecular parameters of the calcium channel blocker, including the choice of heterocyclic ring (4- to 7-membered), substitution patterns on the benzene ring, and stereochemical configuration. These parameter optimizations shift the drug's selectivity profile toward N-type channels while maintaining adequate blocking efficacy, thereby resolving the contradiction between therapeutic effectiveness and cardiovascular safety.
2Object-affected harmful factors
If selective N-type calcium channel blockers are developed, then hypotensive side effects are minimized, but compound selectivity and efficacy must be precisely optimized
Solution Approach 1:
The patent applies segmentation by dividing the calcium channel blocker into distinct functional modules: a heterocyclic amine segment (azetidinyl, pyrrolidinyl, piperidinyl, or hexahydroazepinyl), a linker segment, and a benzenesulfonamide segment with variable substituents. This modular segmentation allows independent optimization of each component's contribution to selectivity and affinity, enabling precise control over N-type channel blocking while minimizing off-target effects on L-type channels.
Solution Approach 2:
The patent systematically varies molecular parameters including the size of the heterocyclic ring (4-7 members), the nature of substituents R1-R7 on the benzene ring, and stereochemical configurations to fine-tune the compound's selectivity profile. This parameter optimization ensures high affinity for N-type channels while maintaining low affinity for L-type channels, thereby achieving the desired selectivity without compromising efficacy.
Data Source
AI summary
The invention relates to azetidinyl, pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula I and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1-R3 and Z are defined as set forth in the specification. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.